Compumedics (ASX:CMP) granted U.S. FDA for Neuroimaging technology
- Compumedics (CMP) has received clearance from the U.S. Food and Drug Administration (FDA) for its neuroimaging technology
- The clearance allows for routine clinical use of the MEG devices, mainly for epilepsy and pre-surgical brain function mapping
- Sites using the technology can now routinely bill private and public insurance plans for the examination
Granted U.S. FDA for Neuroimaging technology
Add CMP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
-0.010(3.85%) |
Mkt cap ! $44.29M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.0¢ | 25.0¢ | $1.217K | 4.869K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 22302 | 26.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.0¢ | 11587 | 2 |
View Market Depth
| Last trade - 10.49am 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
26.0¢ |
Change
-0.010 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 24.5¢ | 26.0¢ | 24.5¢ | 7558 | ||
| Last updated 13.51pm 26/04/2024 ? | |||||
| CMP (ASX) Chart |